Synthesis and biological evaluation of 16E-arylidenosteroids as cytotoxic and anti-aromatase agents

Chemical and Pharmaceutical Bulletin

Volumn 59, Issue 3, 2011, Pages 327-331

  Bansal, Ranju ^a   Guleria, Sheetal ^a   Thota, Sridhar ^a   Hartmann, Rolf Wolfgang ^b   Zimmer, Christina ^b  

^a PANJAB UNIVERSITY   (India)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

16E arylidenosteroid; Aromatase inhibitory activity; Breast cancer; Cancer cell line; Cytotoxic activity; Dehyroepiandrosterone

Indexed keywords

16 [4 [3 (IMIDAZOL 1 YL)PROPOXY] 3 METHOXYBENZYLIDENE] 17 OXO 5 ANDROSTEN 3BETA OL; 16 [4 [3 (IMIDAZOL 1 YL)PROPOXY] 3 METHOXYBENZYLIDENE] 17 OXO 5 ANDROSTEN 3BETA YLACETATIC ACID; 16 [4 [3 (IMIDAZOL 1 YL)PROPOXY] 3 METHOXYBENZYLIDENE] 3BETA PYRROLIDINO 5 ANDROSTEN 17BETA YLACETIC ACID; 16 [4 [3 (IMIDAZOL 1 YL)PROPOXY] 3 METHOXYBENZYLIDENE] 4 ANDROSTENE 3,17 DIONE; 16 [4 [3 (IMIDAZOL 1 YL)PROPOXY] 3 METHOXYBENZYLIDENE] 5 ANDROSTENE 3BETA,17BETA DIOL; 16 [4 [3 (IMIDAZOL 1 YL)PROPOXY] 3 METHOXYBENZYLIDENE] 5 ANDROSTENE 3BETA,17BETA DIOL DIACETATE; AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; IDENOSTEROID DERIVATIVE; STEROID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL;

ANDROSTENEDIOLS; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; STEROIDS;

EID: 79952427860     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.59.327     Document Type: Article

References (19)

1. Sharma S. K., Weizhong Z., Alummoottil V., Douglas N., Abrams A. J. B., McEwan A., Bioorg. Med. Chem. Lett., 18, 5563-5566 (2008).
2. Thompson E. A., Siiteri P. K., J. Biol. Chem., 249, 5373-5378 (1974).
3. Simpson E. R., Mahendroo M. S., Means G. D., Kilgore M. W., Hinshelwood M. M., Graham-Lorence S., Endocr. Rev., 15, 342-355 (1994).
4. Djurendi E., Daljeva J., Sakac M., Canadi J., Santa S. J., Andric S., Klisuric O., Kojic V., Bogdanovic G., Djurendic-Brenesela M., Novakovic S., Gasi K. P., Steroids, 73, 129-138 (2008).
5. Baum M., Budzar A. U., Cuzick J., Forbes J., Houghton J. H., Klijn J. G., Sahmoud T., Lancet, 359, 2131-2139 (2002).
6. Smith I. E., Dowsett M., New Engl. J. Med., 348, 2431-2442 (2003).
7. Plourde P. V., Dyroff M., Dukes M., Breast Cancer Res. Treat., 30, 103-111 (1994).
8. Christiansen R. G., Clinton R. O., Greenbush E., Dean J. W., U.S. Patent 3163641 (1965).
9. Schenider F., Hamsher J., Beyler R. E., Steroids, 8, 553-563 (1966).
10. Numazawa M., Osawa Y., Steroids, 38, 149-159 (1981).
11. Bansal R., Guleria S., Steroids, 73, 1391-1399 (2008).
12. Chattopadhaya R., Jindal D. P., Minu M., Gupta R., Arzneim-Forsch/Drug Res., 54, 551-556 (2004).
13. Dubey S., Piplani P., Jindal D. P., Chem. Biodivers., 1, 1529-1536 (2004).
14. Bansal R., Kumar R. S., Kumar G., Thota S., Thamotharan S., Parthasarathi V., Linden A., J. Heterocycle. Chem., 45, 1789-1795 (2008).
15. Grever M. R., Schepartz S. A., Chabner, B. A., Semin. Oncol., 19, 622-638 (1992).
16. Boyd M. R., Paul K. D., Drug Dev. Res., 34, 91-109 (1995).
17. Thompson E. A., Siiteri P. K., J. Biol. Chem., 249, 5364-5372 (1974).
18. Foster A. B., Jarman M., Leung S., Rowlands M. G., Taylor G. N., J. Med. Chem., 26, 50-54 (1983).
19. Graves P. E., Salhanick H. A., Endocrinology, 105, 52-57 (1979).